Sakar Healthcare Limited (NSE:SAKAR)

Market Cap	6.32B
Revenue (ttm)	1.71B
Net Income (ttm)	148.62M
Shares Out	21.75M
EPS (ttm)	6.85
PE Ratio	42.45
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	46,663
Average Volume	35,035
Open	265.50
Previous Close	269.05
Day's Range	264.25 - 308.15
52-Week Range	210.10 - 374.50
Beta	0.08
RSI	59.01
Earnings Date	May 20, 2025

About Sakar Healthcare

Sakar Healthcare Limited research, develops, manufactures, and markets pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as antacid, antimalerial, anticoagulant, laxative, anthelmintic, bronchodilator, anaesthetic, antidepressant, sedative, adrenergic, anti-infective, diuretics, oxytoci...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2004
• Employees: 325
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SAKAR

Financial Performance

In 2023, Sakar Healthcare's revenue was 1.54 billion, an increase of 14.89% compared to the previous year's 1.34 billion. Earnings were 116.71 million, a decrease of -8.53%.